BlueLinx - BXC Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BlueLinx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BXC shares.
View BXC analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price objectives for BlueLinx's stock. Their BXC share price forecasts range from $105.00 to $127.00. On average, they predict the company's stock price to reach $116.00 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price.
View analysts price targets for BXC or view top-rated stocks among Wall Street analysts.

BlueLinx's stock was trading at $71.11 at the beginning of the year. Since then, BXC shares have decreased by 4.3% and is now trading at $68.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our BXC earnings forecast.

BlueLinx Holdings Inc. (NYSE:BXC) posted its quarterly earnings results on Monday, November, 1st. The construction company reported $4.74 earnings per share for the quarter, beating the consensus estimate of $3.78 by $0.96. The construction company earned $970.84 million during the quarter. BlueLinx had a trailing twelve-month return on equity of 55.64% and a net margin of 6.66%.

ETFs with the largest weight of BlueLinx (NYSE:BXC) stock in their portfolio include Roundhill Acquirers Deep Value ETF (DEEP), iShares U.S. Infrastructure ETF (IFRA), Royce Quant Small-Cap Quality Value ETF (SQLV), First Trust Active Factor Small Cap ETF (AFSM), Hartford Multifactor Small Cap ETF (ROSC), WisdomTree U.S. SmallCap Fund (EES), Janus Henderson Small Cap Growth Alpha ETF (JSML) and iShares Micro-Cap ETF (IWC).

56 employees have rated BlueLinx Chief Executive Officer Mitch Lewis on Glassdoor.com. Mitch Lewis has an approval rating of 49% among the company's employees. This puts Mitch Lewis in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlueLinx investors own include Novavax (NVAX), Micron Technology (MU), Co-Diagnostics (CODX), Livongo Health (LVGO), Intel (INTC), Maxar Technologies (MAXR), Civeo (CVEO), Nautilus (NLS), Sorrento Therapeutics (SRNE) and Hologic (HOLX).

BlueLinx trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXC."

BlueLinx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Voss Capital LLC (6.63%), Dimensional Fund Advisors LP (4.28%), Portolan Capital Management LLC (2.22%), JPMorgan Chase & Co. (2.06%), Geode Capital Management LLC (1.83%) and AQR Capital Management LLC (1.60%). Insiders that own company stock include Carol B Yancey, Kelly Janzen, Kim S Fennebresque, Mitchell B Lewis, Mitchell B Lewis, Nokomis Capital, LLC and Shyam K Reddy.
View institutional ownership trends.

Shares of BXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXC stock can currently be purchased for approximately $68.03.

BlueLinx (NYSE:BXC) has a market capitalization of $616.35 million and generates $4.45 billion in revenue each year. The construction company earns $296.18 million in net income (profit) each year or $30.55 on an earnings per share basis.

The company employs 2,100 workers across the globe.

BlueLinx's mailing address is 1950 SPECTRUM CIRCLE SUITE 300, MARIETTA GA, 30067. The official website for the company is www.bluelinxco.com. The construction company can be reached via phone at (770) 953-7000, via email at ir@audentestx.com, or via fax at 770-221-8902.